Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
α-Hederin is a naturally occurring pentacyclic triterpenoid saponin compound with the molecular formula C41H66O12 and a molar mass of 750.96 g/mol[6][8][10]. It is found in various plant sources including the seeds of Nigella sativa and leaves of Hedera helix (common ivy)[10]. α-Hederin exhibits significant pharmacological activities such as antitumor (anticancer), anti-inflammatory, spasmolytic (muscle relaxant), and anti-infective effects[1][2][3][4]. Its principal mechanism involves inhibiting tumor cell proliferation by inducing apoptosis (programmed cell death), arresting the cell cycle process in cancer cells[1], modulating multiple signaling pathways including JAK/STAT and PI3K/Akt/mTOR[3], affecting lipid metabolism and TGFβ pathways via regulation of vesicular miRNAs[5], and blocking small extracellular vesicle-mediated drug resistance transmission in cancer therapy. Preclinical studies have shown that α-hederin can enhance the efficacy of chemotherapeutic agents such as paclitaxel or 5-fluorouracil by sensitizing tumor cells to these drugs[4][5][10]. It has been studied for its potential use against breast cancer, lung cancer (including non-small cell lung cancer), colorectal cancer, liver cancer as well as for its general anti-infective properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on α-hederin.